<Preoperative medication> [GX-188E: 1st day of week 1,2,4 2mg, GX-I7 1st day of week 2, Pembrolizumab:1st day of week 1,2,4 200mg] Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device Drug 2: GX-I7 GX-I7 1200㎍/kg, intramuscular administration Drug 3: Pembrolizumab pembrolizumab(100mg/4mL/vial), Intravenous administration <Operation> Surgery 2 to 8 weeks after completion of the test medication. <Posr OP CCRT> Physician's discretion
The study is phase II, open label, clinical trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced,Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer